Early trial of experimental cancer combo halted after 21 patients
NCT ID NCT05233436
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested an experimental oral drug (PF-07265028) alone or combined with an immunotherapy injection (sasanlimab) in 21 people with advanced solid tumors, including stomach, lung, and head/neck cancers. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited and no conclusions about effectiveness can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PF-07265028 (oral drug) and sasanlimab (injectable immunotherapy)
- What this could lead to
- If successful, this could point toward a new treatment option for several advanced cancers, potentially shrinking tumors or slowing their growth.
- What could go wrong
- This is a very early Phase 1 trial with only 21 participants, now terminated. It was designed mainly to check safety and dosing, not to prove effectiveness. Many early cancer drugs fail to show benefit in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
HonorHealth Scottsdale Shea Medical Center
Scottsdale, Arizona, 85260, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, 78229, United States
-
The Cancer Institute Hospital of JFCR
Koto, Tokyo, 135-8550, Japan
-
University of Iowa
Iowa City, Iowa, 52242, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can your own immune cells beat advanced cancer?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?